Table 2 Distribution of aberrant (aPC) and normal (nPC) plasma cells in BM samples from MM patients in VGPR, CR and sCR with discrepant MRD results (MRD+ vs MRD) by NGF vs conventional flow-MRD assays

From: Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Case ID

Disease status

Conventional flow

NGF

  

% tPC

% nPC

% aPC

% tPC

% nPCs

% aPC

1

CR

0.01

0.01

0

0.008

0.007

0.0004

2

CR

0.01

0.01

0

0.02

0.02

0.0002

3

CR

0.007

0.007

0

0.007

0.007

0.0003

4

CR

0.04

0.04

0

0.02

0.02

0.0004

5

sCR

0

0

0

0.003

0.002

0.0006

6

CR

0.1

0.1

0

0.1

0.1

0.002

7

CR

0.2

0.2

0

0.2

0.2

0.02

8

sCR

0

0

0

0.002

0.003

0.0002

9

CR

0.9

0.9

0

0.6

0.6

0.005

10

CR

0.2

0.2

0

0.06

0.06

0.0004

11

VGPR

0

0

0

0.01

0.01

0.0007

12

CR

0

0

0

0.01

0.01

0.006

13

sCR

0.2

0.2

0

0.2

0.2

0.005

14

sCR

0.03

0.03

0

0.03

0.03

0.002

15

CR

0.1

0.1

0

0.07

0.04

0.03

16

VGPR

0

0

0

0.009

0.008

0.001

17

CR

0.1

0

0

0.004

0.003

0.001

18

CR

0.04

0

0

0.01

0.01

0.0002

19

CR

0.09

0.08

0.01

0.05

0.05

0

20

CR

0.1

0.1

0.006

0.1

0.1

0

21

CR

0.4

0.3

0.02

0.3

0.3

0

  1. Abbreviations: aPC, aberrant plasma cell; BM, bone marrow; CR, complete response; MM, multiple myeloma; MRD, minimal residual disease; NGF, next generation flow; nPC, normal plasma cell; sCR, stringent CR; tPC, total plasma cells; VGPR, very good partial response.